MOR202

MOR202 is a human monoclonal HuCAL antibody directed against CD38 in clinical development for the treatment of multiple myeloma (MM) and potentially other cancers

MOR202 is currently under clinical investigation in patients with relapsed or refractory multiple myeloma. We believe MOR202 offers a potentially differentiated safety and administration profile relative to infusion site reaction and infusion time of other agents targeting CD38. Scientific research suggests that an anti-CD38 antibody such as MOR202 may have therapeutic activity in solid tumors including non-small cell lung cancer. End of 2017, MorphoSys entered into an exclusive regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in Greater China.

 

Mode of action

CD38 is one of the most strongly and uniformly expressed antigens on the surface of malignant plasma cells, and is an established diagnostic marker for multiple myeloma. Scientific research suggest that an anti-CD38 antibody may have therapeutic activity in solid tumors including non-small cell lung cancer, or NSCLC, or autoimmune and other diseases driven by autoantibodies such as light chain amyloidosis or systemic lupus erythematosus. Key activities of MOR202 are antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) mediated killing of cancer cells. The antibody does not involve complement dependent cytotoxicity, or CDC, an additional mechanism involved in tumor cell killing. In addition, pre-clinical data point to a low NK-cell depletion.

 

The figure depicts the suggested mechanism of action of MOR202

The therapeutic field: Multiple Myeloma and solid tumors

Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they displace and suppress healthy blood progenitor cell populations. Multiple myeloma is also characterized by destructive lytic bone lesions (rounded, punched-out areas of bone), diffuse osteoporosis, bone pain, and the production of abnormal proteins, which accumulate in the urine. Anemia is also present in most multiple myeloma patients at the time of diagnosis and during follow-up. Anemia in multiple myeloma is multifactorial, and is secondary to bone marrow replacement by malignant plasma cells, chronic inflammation, relative erythropoietin deficiency, and vitamin deficiency.

There is currently no standard multiple myeloma treatment. A patient’s individual treatment plan is based on such factors as age and general health, results of laboratory and cytogenetic (genomic) tests, symptoms and disease complications, prior myeloma treatment, patient’s lifestyle, goals, views on quality of life, and personal preferences. In addition, many cancer centers have developed their own guidelines for treating myeloma.

The introduction of CD38 monoclonal antibodies to the treatment landscape of multiple myeloma, highlighted by the approval of daratumumab, might be transformative. Based on their distinct mechanisms of action, generally favorable toxicity profile, and single agent activity, CD38 antibodies are considered attractive partners in combination regimens.
Beyond multiple myeloma, scientific research suggests that an anti-CD38 antibody such as potentially MOR202 may have therapeutic activity in solid tumors including non-small cell lung cancer (NSCLC).

 

Phase 1/2a dose escalation study in relapsed/refractory multiple myeloma

MOR202 is currently under clinical investigation in a phase 1/2a, open-label, multi-center, dose-escalation study conducted in several sites in Germany and Austria. The study is evaluating the safety and preliminary efficacy of MOR202 alone and in combination with the immunomodulatory drugs pomalidomide (Pom) and lenalidomide (Len) plus dexamethasone (Dex) in patients with relapsed/refractory multiple myeloma. The primary endpoints of the trial are the safety, tolerability and recommended dose of MOR202 alone and in combination with the IMiDs. Secondary outcome measures are pharmacokinetics and preliminary efficacy based on overall response rate, duration of response, time-to-progression, and progression-free survival.

 

Partnering

In November 2017, MorphoSys and I-Mab entered into an exclusive regional licensing agreement to develop and commercialize MOR202 in Greater China (China, Taiwan, Hong Kong and Macao). I-Mab Biopharma has assumed exclusive responsibility for all subsequent development and commercialization of MOR202 in the agreed territory. I-Mab Biopharma intends to start clinical development of MOR202 in patients with multiple myeloma in China by the end of 2018.

 

Poster clinical data of MOR202 presentet at 2017 ASCO Annual Meeting
(PDF, 728 KB)
Poster clinical data of MOR202 presented at 2016 DGHO Annual Meeting
(PDF, 232 KB)
Poster clinical data of MOR202 presented at the 2016 EHA Conference
(PDF, 1.5 MB)
Poster clinical data of MOR202 presented at 2016 ASCO Annual Meeting
(PDF, 203 KB)